ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
ChromaDex Corp. (NASDAQ:CDXC) has launched the Niagen+ NAD+ Test Kit, exclusively available through its healthcare practitioner (HCP) channel. This innovative kit allows practitioners to measure patient blood NAD+ levels, enabling more personalized protocols using ChromaDex's NAD+-boosting products, Tru Niagen® and Niagen+.
The test kit features advanced dried blood spot (DBS) assay technology, ensuring NAD+ sample stability during transport. Analysis is conducted using high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS) at a CLIA and CAP accredited laboratory. Results are available to both patients and doctors in about two weeks through the 1health platform.
This launch represents a significant advancement in NAD+ therapy, allowing practitioners to track NAD+ changes over time and create more effective patient protocols.
ChromaDex Corp. (NASDAQ:CDXC) ha lanciato il Niagen+ Kit di Test NAD+, disponibile esclusivamente tramite il suo canale di professionisti sanitari (HCP). Questo kit innovativo consente ai professionisti di misurare i livelli di NAD+ nel sangue dei pazienti, permettendo protocolli più personalizzati utilizzando i prodotti a base di NAD+ di ChromaDex, Tru Niagen® e Niagen+.
Il kit di test è dotato di una tecnologia avanzata di saggio su campione di sangue essiccato (DBS), garantendo la stabilità del campione di NAD+ durante il trasporto. L'analisi viene effettuata utilizzando la cromatografia liquida ad alta risoluzione/spettrometria di massa tandem (LC-MS/MS) in un laboratorio accreditato CLIA e CAP. I risultati sono disponibili per pazienti e medici in circa due settimane attraverso la piattaforma 1health.
Questo lancio rappresenta un significativo progresso nella terapia NAD+, consentendo ai professionisti di monitorare le variazioni di NAD+ nel tempo e di creare protocolli più efficaci per i pazienti.
ChromaDex Corp. (NASDAQ:CDXC) ha lanzado el Niagen+ Kit de Prueba NAD+, disponible exclusivamente a través de su canal de profesionales de la salud (HCP). Este kit innovador permite a los profesionales medir los niveles de NAD+ en la sangre de los pacientes, lo que permite protocolos más personalizados utilizando los productos potenciadores de NAD+ de ChromaDex, Tru Niagen® y Niagen+.
El kit de prueba cuenta con una avanzada tecnología de análisis de muestra de sangre seca (DBS), asegurando la estabilidad de la muestra de NAD+ durante el transporte. El análisis se lleva a cabo utilizando cromatografía líquida de alta resolución/espectrometría de masas en tándem (LC-MS/MS) en un laboratorio acreditado por CLIA y CAP. Los resultados están disponibles para pacientes y médicos en aproximadamente dos semanas a través de la plataforma 1health.
Este lanzamiento representa un avance significativo en la terapia de NAD+, permitiendo a los profesionales rastrear los cambios de NAD+ a lo largo del tiempo y crear protocolos más efectivos para los pacientes.
ChromaDex Corp. (NASDAQ:CDXC)는 Niagen+ NAD+ 테스트 키트를 출시했습니다. 이 키트는 의료 전문가(HCP) 채널을 통해서만 이용할 수 있습니다. 이 혁신적인 키트는 의료 전문가가 환자의 혈액 내 NAD+ 수준을 측정할 수 있게 하여, ChromaDex의 NAD+ 증진 제품인 Tru Niagen® 및 Niagen+을 사용한 보다 개인화된 프로토콜을 가능하게 합니다.
이 테스트 키트는 운송 중 NAD+ 샘플의 안정성을 보장하는 고급 건조 혈액 샘플(DBS) 분석 기술을 특징으로 합니다. 분석은 CLIA 및 CAP 인증을 받은 실험실에서 고해상도 액체 크로마토그래피/탠덤 질량 분광법(LC-MS/MS)을 사용하여 수행됩니다. 결과는 약 2주 후에 1health 플랫폼을 통해 환자와 의사 모두에게 제공됩니다.
이번 출시로 NAD+ 치료의 중요한 발전이 이루어져, 의료 전문가가 시간에 따라 NAD+ 변화를 추적하고 환자 프로토콜을 보다 효과적으로 만드는 것이 가능해졌습니다.
ChromaDex Corp. (NASDAQ:CDXC) a lancé le Kit de Test Niagen+ NAD+, disponible exclusivement par le biais de son canal de praticiens de santé (HCP). Ce kit innovant permet aux praticiens de mesurer les niveaux de NAD+ dans le sang des patients, facilitant ainsi des protocoles plus personnalisés utilisant les produits à base de NAD+ de ChromaDex, à savoir Tru Niagen® et Niagen+.
Le kit de test intègre une technologie avancée d'analyse des échantillons de sang sec (DBS), garantissant la stabilité des échantillons de NAD+ durant le transport. L'analyse est effectuée par chromatographie liquide haute résolution/spectrométrie de masse en tandem (LC-MS/MS) dans un laboratoire accrédité CLIA et CAP. Les résultats sont accessibles aux patients et aux médecins en environ deux semaines via la plateforme 1health.
Ce lancement représente une avancée significative dans la thérapie NAD+, permettant aux praticiens de suivre les variations de NAD+ au fil du temps et de créer des protocoles plus efficaces pour les patients.
ChromaDex Corp. (NASDAQ:CDXC) hat das Niagen+ NAD+ Test Kit eingeführt, das ausschließlich über den Kanal von Gesundheitsdienstleistern (HCP) erhältlich ist. Dieses innovative Kit ermöglicht es Praktikern, die NAD+ Werte im Blut der Patienten zu messen und personalisierte Protokolle mit den NAD+-fördernden Produkten von ChromaDex, Tru Niagen® und Niagen+, zu entwickeln.
Das Testkit verwendet fortschrittliche Technologien zur Analyse von getrockneten Blutproben (DBS), die die Stabilität der NAD+ Proben während des Transports sicherstellen. Die Analyse erfolgt mithilfe von hochauflösender Flüssigkeitschromatographie/Tandem-Massenspektrometrie (LC-MS/MS) in einem CLIA- und CAP-zertifizierten Labor. Die Ergebnisse sind nach etwa zwei Wochen über die 1health-Plattform sowohl für Patienten als auch für Ärzte verfügbar.
Dieser Launch stellt einen erheblichen Fortschritt in der NAD+-Therapie dar, der es Praktikern ermöglicht, NAD+-Veränderungen im Laufe der Zeit zu verfolgen und effektivere Behandlungsprotokolle für Patienten zu erstellen.
- Launch of innovative Niagen+ NAD+ Test Kit for healthcare practitioners
- Exclusive availability through HCP channel may increase professional adoption
- Advanced DBS assay technology ensures accurate NAD+ measurement
- Partnership with 1health for efficient kit fulfillment and result delivery
- None.
The launch of ChromaDex's Niagen+ NAD+ Test Kit represents a significant step forward in the personalized healthcare sector. The exclusivity of the product to healthcare practitioners (HCPs) ensures a targeted market approach, which could foster significant uptake within the professional healthcare community. This exclusivity can create a sense of scarcity and prestige, potentially driving demand among HCPs eager to provide state-of-the-art diagnostics to their patients.
From a market perspective, this product could enhance ChromaDex's brand reputation as a leader in NAD+ research and commercialization. The integration with 1health's robust platform also suggests a seamless user experience, which is important for adoption rates. Moreover, the precision promised by the DBS card technology addresses a significant pain point in NAD+ measurement, potentially setting a new industry standard.
It's also noteworthy that the kit is designed to work with ChromaDex’s existing product lines, Tru Niagen and Niagen+, creating potential for cross-selling and increased revenue streams. The company's focus on accurate, clinically-validated results positions this product as a potentially valuable tool for practitioners, which could translate into sustained demand and long-term profitability.
However, investors should be aware that the product has not been cleared or approved by the FDA, which might limit its market potential and adoption rate, especially among more conservative healthcare practitioners.
The introduction of the Niagen+ NAD+ Test Kit is a substantial advancement in the field of personalized medicine, particularly in the domain of healthy aging and NAD+ research. The ability to measure NAD+ levels accurately and reliably using dried blood spot (DBS) assay technology could significantly improve patient outcomes by allowing for tailored supplementation protocols.
NAD+ is a critical coenzyme involved in cellular energy production and metabolism and its levels are known to decline with age. The ability to monitor these levels accurately through a stable and reliable testing method could enable practitioners to make more informed decisions about NAD+ boosting therapies, potentially improving patient health outcomes.
The CLIA and CAP accreditation of the testing laboratory adds a layer of trust and validation, ensuring that the results are reliable and can be used to guide clinical decisions. The involvement of a reputable platform like 1health further enhances the credibility and potential utility of this test kit.
However, it is important to note that the product is not intended to diagnose or treat any conditions and it has not been tested on individuals with health conditions. This limitation may restrain its applicability in broader clinical settings, potentially impacting its acceptance among healthcare professionals.
The launch of the Niagen+ NAD+ Test Kit is a strategic move by ChromaDex that could have meaningful financial implications. Firstly, by offering an exclusive product to healthcare practitioners, ChromaDex not only taps into a specialized market but also builds brand loyalty among professionals who are likely to recommend their products.
The successful integration with 1health ensures efficient fulfillment and result delivery, which can streamline operations and potentially reduce costs associated with logistics and customer service. This operational efficiency could positively impact ChromaDex's margins.
From a revenue perspective, the test kit complements ChromaDex’s existing product lines like Tru Niagen and Niagen+, offering potential for upselling and increased consumer lifetime value. If the test kit gains traction, it could lead to higher sales of related NAD+ boosting therapies, thereby driving revenue growth.
However, the lack of FDA approval might limit the kit's market penetration and could be a point of concern for investors. This regulatory hurdle means the product might primarily appeal to early adopters and more progressive practitioners, rather than becoming a mainstream diagnostic tool.
Results from the at-home test kit are available to HCPs and their patients through 1health
ChromaDex launches Niagen+ NAD+ Test Kit, one of the most reliable methods for patients to measure and track their NAD+ levels (Photo: Business Wire)
Tru Niagen is a suite of oral dietary supplements featuring Niagen (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor available. Niagen+ features pharmaceutical-grade Niagen (patented nicotinamide riboside chloride or NRC) and will soon be available as Niagen IV and injections exclusively at clinics from
Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, noted, "Our healthcare practitioners have requested a tool to measure blood NAD+ levels, and we believe this is the best product now available on the market."
Setting a new standard in analytical NAD+ measurement methods, the Niagen+ NAD+ Test Kit features cutting-edge dried blood spot (DBS) assay technology, ensuring the stability of NAD+ samples during transport for precise and accurate results. Other test kits use a less reliable DBS card, which requires adding a fixer solution to stabilize NAD+, which often degrades during the DBS drying process. With this innovative Niagen+ NAD+ test, HCPs can provide patients with personalized and effective protocols by more accurately tracking NAD+ changes over time.
Key Niagen+ NAD+ Test Kit features:
- Innovative test card technology: A unique blood spot test card maintains the stability of NAD+ throughout the transport process and ensures accurate measurement.
- Baseline and progress tracking: While each HCP will determine the patient protocol, the test can be used to understand NAD+ levels before Tru Niagen NAD+-boosting and/or Niagen IV and injections to establish a baseline and again after NAD+ boosting therapy to track changes.
- Validated, trusted results: Analyses are conducted at a Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) accredited clinical genomics and biochemical testing laboratory with expertise in mass spec-based assays.
- Precision analysis: NAD+ measurements are conducted on the blood sample affixed to the DBS card using the gold standard analytical method, high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS).
How it works:
HCPs will provide patients with an at-home Niagen+ NAD+ Test Kit, which patients will register on the 1health platform. Once registered, the patient will follow the instructions within the kit to procure a sample with the DBS card and send it to the lab using a prepaid envelope. Results will be available to both patients and doctors in about two weeks through 1health.
Mehdi Maghsoodnia, CEO at 1health, emphasized the critical role of 1health’s platform in the successful launch of the Niagen+ NAD+ Test Kit. “We are proud to partner with ChromaDex to bring this innovative testing solution to healthcare practitioners. Our robust software seamlessly integrates with both the warehouse and the lab, ensuring efficient fulfillment of kits and accurate delivery of results. This collaboration provides invaluable insights for practitioners aiming to optimize their patients' NAD+ levels, enabling personalized and effective NAD+ boosting protocols, such as Tru Niagen oral supplementation and soon Niagen IV and injection, to maximize therapeutic outcomes.”
Practitioners can learn more about the test kit, view all HCP products, and find research on clinical practice applications at www.truniagenpro.com. To learn more about ChromaDex, please visit www.chromadex.com.
*This product is not intended to diagnose, prevent, or treat a condition. Measurements and statistics are intended for informational and educational purposes only, to support general health and wellness. This product has not been tested with individuals with health conditions and has not been cleared or approved by the
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the Niagen+ NAD+ Test Kit, now available exclusively through the company’s healthcare practitioner (HCP) channel. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.
†Based on the top-selling dietary supplement brands by revenue per the largest
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723490080/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
What is the Niagen+ NAD+ Test Kit launched by ChromaDex (NASDAQ:CDXC)?
How does the Niagen+ NAD+ Test Kit benefit healthcare practitioners and patients?
When will the results from the Niagen+ NAD+ Test Kit be available?
Where can healthcare practitioners learn more about the Niagen+ NAD+ Test Kit and other ChromaDex (NASDAQ:CDXC) products?
